Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Astellas Pharma Unsp/Adr (OP:ALPMY)

15.88 -0.61 (-3.72%)
Streaming Delayed Price Updated: 11:46 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astellas Pharma Unsp/Adr

< Previous 1 2 3 Next >
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power ↗
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism. 
Via Benzinga
News headline image
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients ↗
Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with bladder cancer. 
Via Investor's Business Daily
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for pivotal trial. 
Via Benzinga
News headline image
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy. 
Via Benzinga
News headline image
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study ↗
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported. 
Via Benzinga
News headline image
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre ↗
JP Morgan sees steady growth for Apellis' Syfovre, lowering the price target to $45. Syfovre sales hit $167.8M in Q4, with over 94,000 doses delivered. 
Via Benzinga
News headline image
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo ↗
Pfizer and Astellas' Padcev-Keytruda combo showed durable survival benefits in urothelial cancer, with a higher response rate and no new safety concerns. 
Via Benzinga
News headline image
Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise ↗
Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers. 
Via Benzinga
News headline image
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact ↗
Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
Via Benzinga
News headline image
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst ↗
It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead. 
Via The Motley Fool
News headline image
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales... 
Via Benzinga
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
News headline image
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data ↗
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
News headline image
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential ↗
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months. 
Via Talk Markets
News headline image
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
Via Talk Markets
News headline image
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
News headline image
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks ↗
The companies studied a combination of Keytruda and Padcev in bladder cancer patients. 
Via Investor's Business Daily
News headline image
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... 
Via Benzinga
News headline image
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years ↗
The multibillionaire's portfolio features some moneymaking ideas. 
Via The Motley Fool
News headline image
Why Is Seagen Stock Trading Higher Today? ↗
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC:  
Via Benzinga
News headline image
Seagen Pops After Scoring A 'Must-Win' For Its $43 Billion Takeover By Pfizer ↗
The companies tested a key combination in patients with previously untreated bladder cancer. 
Via Investor's Business Daily
News headline image
What's Going On With Neurology Focused Taysha Gene Therapies Stock Today? ↗
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected  
Via Benzinga
News headline image
Here's Why Embattled Apellis Stock, A Former Highflier, Just Took Another Hit To The Chin ↗
The company is already under scrutiny after reports of side effects tied to Syfovre. 
Via Investor's Business Daily
News headline image
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs ↗
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
News headline image
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas ↗
Cullgen will collaborate with Astellas Pharma to discover protein degraders in a deal worth up to $1.9 billion. Meanwhile, Cholesgen formed a collaboration with AstraZeneca to develop new candidates... 
Via Talk Markets
News headline image
Astellas Pharma Licenses Promising Gene Therapy KT430 from Kate Therapeutics Amidst Clinical Hurdles ↗
Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) decided to license and advance a gene therapy from Kate Therapeutics for a debilitating muscle disorder known as  
Via Benzinga
News headline image
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
News headline image
Why Shares of Annexon Are Plummeting Thursday ↗
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.